08:41 AM EDT, 03/13/2025 (MT Newswires) -- Tempest Therapeutics ( TPST ) said Thursday that the mid-stage clinical trial of TPST-1495 for the treatment of familial adenomatous polyposis has received a "study may proceed" letter from the US Food and Drug Administration.

The clinical-stage company said the Cancer Prevention Clinical Trials Network will run the mid-stage study, which will start this year and funded by the National Cancer Institute Division of Cancer Prevention.

Shares of the company were up more than 1% in recent premarket activity on Thursday.